These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15006369)

  • 1. Crucial amides for dimerization inhibitors of HIV-1 protease.
    Bowman MJ; Chmielewski J
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1395-8. PubMed ID: 15006369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sidechain-linked inhibitors of HIV-1 protease dimerization.
    Bowman MJ; Chmielewski J
    Bioorg Med Chem; 2009 Feb; 17(3):967-76. PubMed ID: 18337105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
    Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
    Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.
    Lee SG; Chmielewski J
    Chem Biol; 2006 Apr; 13(4):421-6. PubMed ID: 16632254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching between allosteric and dimerization inhibition of HIV-1 protease.
    Bowman MJ; Byrne S; Chmielewski J
    Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors.
    Hwang YS; Chmielewski J
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4297-300. PubMed ID: 15261290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
    J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring inhibitor-induced conformational population shifts in HIV-1 protease by pulsed EPR spectroscopy.
    Blackburn ME; Veloro AM; Fanucci GE
    Biochemistry; 2009 Sep; 48(37):8765-7. PubMed ID: 19691291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity mapping of HIV-1 protease by reduced bond inhibitors.
    Majer P; Urban J; Gregorová E; Konvalinka J; Novek P; Stehlíková J; Andreánsky M; Sedlácek J; Strop P
    Arch Biochem Biophys; 1993 Jul; 304(1):1-8. PubMed ID: 8323274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases.
    Bannwarth L; Rose T; Dufau L; Vanderesse R; Dumond J; Jamart-Grégoire B; Pannecouque C; De Clercq E; Reboud-Ravaux M
    Biochemistry; 2009 Jan; 48(2):379-87. PubMed ID: 19105629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational proteomics analysis of binding mechanisms and molecular signatures of the HIV-1 protease drugs.
    Verkhivker G
    Artif Intell Med; 2009; 45(2-3):197-206. PubMed ID: 18926674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of 3-aminolactams: design, synthesis, and biological evaluation of a library of potential dimerisation inhibitors of HIV1-protease.
    Pinyol E; Frutos S; Grillo-Bosch D; Giralt E; Clotet B; Esté JA; Diez A
    Org Biomol Chem; 2012 Jun; 10(22):4348-54. PubMed ID: 22546925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimerization inhibitors of HIV-1 protease.
    Boggetto N; Reboud-Ravaux M
    Biol Chem; 2002 Sep; 383(9):1321-4. PubMed ID: 12437124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A priori molecular descriptors in QSAR: a case of HIV-1 protease inhibitors. II. Molecular graphics and modeling.
    Kiralj R; Ferreira MM
    J Mol Graph Model; 2003 Jun; 21(6):499-515. PubMed ID: 12676237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amide hydrogen exchange in HIV-1 subtype B and C proteases--insights into reduced drug susceptibility and dimer stability.
    Naicker P; Stoychev S; Dirr HW; Sayed Y
    FEBS J; 2014 Dec; 281(24):5395-410. PubMed ID: 25283307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
    Bannwarth L; Kessler A; Pèthe S; Collinet B; Merabet N; Boggetto N; Sicsic S; Reboud-Ravaux M; Ongeri S
    J Med Chem; 2006 Jul; 49(15):4657-64. PubMed ID: 16854071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.